SUNRISE, Fla., Nov. 4, 2008 (GLOBE NEWSWIRE) -- Bioheart, Inc. (Nasdaq:BHRT), a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases, today announced that Chief Financial Officer William Kline will present its corporate presentation at the Rodman & Renshaw 10th Annual Healthcare Conference in New York City, November 12, 2008 at 4:30 p.m. ET. The conference will be held at the New York Palace Hotel in New York City.
An audio webcast of the presentation will be available during the event via the Company's website, www.bioheartinc.com. The audio webcast may be accessed under the "News & Events" section of the Company's website. The webcast will be available live and by replay one hour after the presentation on the Company's website and archived for 90 days.
Rodman & Renshaw announced earlier this week that former President Bill Clinton will present the Keynote Speech at its Annual Global Investment Conference. President Clinton will open Rodman & Renshaw's most expansive conference yet, with over 550 growth companies presenting and over 3,500 registered attendees.
About Bioheart, Inc.
Bioheart, Inc. (Nasdaq:BHRT) is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient's quality of life and reduce health care costs and hospitalizations. Specific to biotechnology, the Company is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The Company's lead product candidate is MyoCell(r), an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell(r) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins. For more information on Bioheart, visit http://www.bioheartinc.com.
MyoCell and MyoCell SDF-1 are trademarks of Bioheart, Inc.